These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 16798054)

  • 1. Estimating the value of novel interventions for Parkinson's disease: an early decision-making model with application to dopamine cell replacement.
    Hjelmgren J; Ghatnekar O; Reimer J; Grabowski M; Lindvall O; Persson U; Hagell P
    Parkinsonism Relat Disord; 2006 Oct; 12(7):443-52. PubMed ID: 16798054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cost and quality aspects in the treatment of Parkinson's disease].
    Müller T; Dodel R; Fritze J
    Z Arztl Fortbild Qualitatssich; 2006; 100(4):291-5. PubMed ID: 16878798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Societal value of stem cell therapy in stroke--a modeling study.
    Svensson J; Ghatnekar O; Lindgren A; Lindvall O; Norrving B; Persson U; Kokaia Z
    Cerebrovasc Dis; 2012; 33(6):532-9. PubMed ID: 22571941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A value-based medicine cost-utility analysis of idiopathic epiretinal membrane surgery.
    Gupta OP; Brown GC; Brown MM
    Am J Ophthalmol; 2008 May; 145(5):923-8. PubMed ID: 18329000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-utility analysis of Parkinson's disease.
    Shan DE; Wu HC; Chan LY; Liu KD
    Acta Neurol Taiwan; 2011 Mar; 20(1):65-72. PubMed ID: 21249581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective comparative study on cost-effectiveness of subthalamic stimulation and best medical treatment in advanced Parkinson's disease.
    Valldeoriola F; Morsi O; Tolosa E; Rumià J; Martí MJ; Martínez-Martín P
    Mov Disord; 2007 Nov; 22(15):2183-91. PubMed ID: 17724747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative use of recombinant human erythropoietin in pediatric orthopedics: a decision model for long-term outcomes.
    Vitale MG; Roye BD; Ruchelsman DE; Roye DP
    Spine J; 2007; 7(3):292-300. PubMed ID: 17482112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An economic model of Parkinson's disease: implications for slowing progression in the United States.
    Johnson SJ; Diener MD; Kaltenboeck A; Birnbaum HG; Siderowf AD
    Mov Disord; 2013 Mar; 28(3):319-26. PubMed ID: 23404374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
    Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
    Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost utility of allogeneic stem cell transplantation with matched unrelated donor versus treatment with imatinib for adult patients with newly diagnosed chronic myeloid leukaemia.
    Breitscheidel L
    J Med Econ; 2008; 11(4):571-84. PubMed ID: 19450068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An estimate of lifelong costs and QALYs in renal replacement therapy based on patients' life expectancy.
    Kontodimopoulos N; Niakas D
    Health Policy; 2008 Apr; 86(1):85-96. PubMed ID: 17996975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of a model analysis to estimate cost utility and value of information for intravenous immunoglobulin in Canadian adults with chronic immune thrombocytopenic purpura.
    Xie F; Blackhouse G; Assasi N; Campbell K; Levin M; Bowen J; Tarride JE; Pi D; Goeree R
    Clin Ther; 2009 May; 31(5):1082-91; discussion 1066-8. PubMed ID: 19539109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The value-based medicine comparative effectiveness and cost-effectiveness of penetrating keratoplasty for keratoconus.
    Roe RH; Lass JH; Brown GC; Brown MM
    Cornea; 2008 Oct; 27(9):1001-7. PubMed ID: 18812762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Markov model assessing the effectiveness and cost-effectiveness of FOLFOX compared with FOLFIRI for the initial treatment of metastatic colorectal cancer.
    Tumeh JW; Shenoy PJ; Moore SG; Kauh J; Flowers C
    Am J Clin Oncol; 2009 Feb; 32(1):49-55. PubMed ID: 19194125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Indirect costs in idiopathic Parkinson's disease].
    Barth F; Baum B; Bremen D; Meuser T; Jost WH
    Fortschr Neurol Psychiatr; 2005 Apr; 73(4):187-91. PubMed ID: 15806436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic evaluation of sevelamer in patients with end-stage renal disease.
    Manns B; Klarenbach S; Lee H; Culleton B; Shrive F; Tonelli M
    Nephrol Dial Transplant; 2007 Oct; 22(10):2867-78. PubMed ID: 17595182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States.
    Rein DB; Wittenborn JS; Lee PP; Wirth KE; Sorensen SW; Hoerger TJ; Saaddine JB
    Ophthalmology; 2009 May; 116(5):823-32. PubMed ID: 19285730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Impact of motor and non-motor symptoms on the direct costs of Parkinson's disease].
    Cubo E; Martínez Martin P; González M; Frades B;
    Neurologia; 2009; 24(1):15-23. PubMed ID: 19003550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost-effectiveness of hormone therapy in younger and older postmenopausal women.
    Salpeter SR; Buckley NS; Liu H; Salpeter EE
    Am J Med; 2009 Jan; 122(1):42-52.e2. PubMed ID: 19114171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cost-effectiveness of an early interventional strategy in non-ST-elevation acute coronary syndrome based on the RITA 3 trial.
    Henriksson M; Epstein DM; Palmer SJ; Sculpher MJ; Clayton TC; Pocock SJ; Henderson RA; Buxton MJ; Fox KA
    Heart; 2008 Jun; 94(6):717-23. PubMed ID: 18032459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.